lemzoparlimab

I-Mab reports positive data from Phase II myelodysplastic syndrome trial
Clinical Trials Arena
Mon, 09/12/22 - 10:45 am
I-Mab
clinical trials
lemzoparlimab
myelodysplastic syndrome
AbbVie has 47 reasons for its $2B cancer immunotherapy partnership with I-Mab
MedCity News
Sun, 09/6/20 - 07:19 pm
AbbVie
I-Mab Biopharma
Forty Seven
lemzoparlimab
cancer immunotherapy